2022
Serotonergic modulation of effective connectivity in an associative relearning network during task and rest
Reed MB, Klöbl M, Godbersen GM, Handschuh PA, Ritter V, Spurny-Dworak B, Unterholzner J, Kraus C, Gryglewski G, Winkler D, Seiger R, Vanicek T, Hahn A, Lanzenberger R. Serotonergic modulation of effective connectivity in an associative relearning network during task and rest. NeuroImage 2022, 249: 118887. PMID: 34999203, DOI: 10.1016/j.neuroimage.2022.118887.Peer-Reviewed Original ResearchConceptsRight angular gyrusAnterior cingulate cortexEffective connectivityRight insulaCognitive flexibilityAngular gyrusCingulate cortexAssociative learning taskAssociative learningLearning taskTask connectivityLearning phaseInsulaGray matter volume changesSelective serotonin reuptake inhibitor escitalopramDouble-blind designNeuroplastic changesGyrusTaskParticipantsSSRI intakeCortexEffective connectionSerotonergic modulationConnectivity
2019
Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging
Gryglewski G, Klöbl M, Berroterán-Infante N, Rischka L, Balber T, Vanicek T, Pichler V, Kautzky A, Klebermass EM, Reed MB, Vraka C, Hienert M, James GM, Silberbauer L, Godbersen GM, Unterholzner J, Michenthaler P, Hartenbach M, Winkler-Pjrek E, Wadsak W, Mitterhauser M, Hahn A, Hacker M, Kasper S, Lanzenberger R. Modeling the acute pharmacological response to selective serotonin reuptake inhibitors in human brain using simultaneous PET/MR imaging. European Neuropsychopharmacology 2019, 29: 711-719. PMID: 31076187, DOI: 10.1016/j.euroneuro.2019.04.001.Peer-Reviewed Original ResearchConceptsSelective serotonin reuptake inhibitorsSerotonin reuptake inhibitorsReuptake inhibitorsPharmacological responsePharmacological imagingFunctional MRIRandomized double-blind designResting-state functional MRIAcute pharmacological responsesCitalopram plasma concentrationsPrevalent neuropsychiatric conditionsDouble-blind designMechanism of actionPlacebo scansInfusion paradigmPlasma levelsSSRI effectsDrug challengePatient outcomesPlasma concentrationsDrug infusionInfluence treatmentConstant infusionLarger sample sizePET/MR scans
2016
Chapter 1 An Introduction to Clinical Research Concepts
Nadkarni P. Chapter 1 An Introduction to Clinical Research Concepts. 2016, 1-24. DOI: 10.1016/b978-0-12-803130-8.00001-4.Peer-Reviewed Original Research
2014
(S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling
Sladky R, Spies M, Hoffmann A, Kranz G, Hummer A, Gryglewski G, Lanzenberger R, Windischberger C, Kasper S. (S)-citalopram influences amygdala modulation in healthy subjects: a randomized placebo-controlled double-blind fMRI study using dynamic causal modeling. NeuroImage 2014, 108: 243-250. PMID: 25536499, DOI: 10.1016/j.neuroimage.2014.12.044.Peer-Reviewed Original ResearchConceptsOrbitofrontal cortexDynamic causal modelingHealthy subjectsDouble-blind fMRI studyCortico-limbic circuitsMagnetic resonance imaging (MRI) scanningAmygdala activationDouble-blind designPharmaceutical treatment optionsFunctional magnetic resonance imaging (fMRI) scanningEmotional face discrimination taskAmygdala modulationNeurophysiologic functionTreatment optionsPsychiatric disordersModulatory effectsCitalopramFunctional MRI dataEscitalopramDiscrimination taskEffective connectivity methodsFMRI studyRegulatory effectsEffective connectivityDifferential effects‘Can you look me in the face?’ Short-term SSRI Administration Reverts Avoidant Ocular Face Exploration in Subjects at Risk for Psychopathology
Di Simplicio M, Doallo S, Costoloni G, Rohenkohl G, Nobre A, Harmer C. ‘Can you look me in the face?’ Short-term SSRI Administration Reverts Avoidant Ocular Face Exploration in Subjects at Risk for Psychopathology. Neuropsychopharmacology 2014, 39: 3059-3066. PMID: 25035080, PMCID: PMC4229577, DOI: 10.1038/npp.2014.159.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalysis of VarianceAntisocial Personality DisorderCitalopramDiscrimination, PsychologicalDouble-Blind MethodEye MovementsFacial ExpressionFemaleHumansMalePersonality InventoryPsychiatric Status Rating ScalesRecognition, PsychologySelective Serotonin Reuptake InhibitorsStatistics as TopicSurveys and QuestionnairesVisual Analog ScaleYoung AdultConceptsFacial stimuliOcular explorationStudy 2Study 1Serotonin reuptake inhibitor citalopramRecognition of positive emotionsReduced eye gazeEysenck Personality QuestionnaireReuptake inhibitor citalopramLow neuroticism scoresNegative facial expressionsEye gaze movementsDouble-blind designHappy facesSSRI administrationFear expressionHigh neuroticismInhibitor citalopramPersonality QuestionnaireNeuroticism scoresEmotional stimuliInterpersonal difficultiesFace stimuliSocial stimuliFace exploration
2008
Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease
Brewer G, Askari F, Lorincz M, Carlson M, Schilsky M, Kluin K, Hedera P, Moretti P, Fink J, Tankanow R, Dick R, Sitterly J. Tetrathiomolybdate versus Trientine in the Initial Treatment of Neurologic Wilson's Disease. 2008, 153-166. DOI: 10.1017/cbo9780511666971.010.Peer-Reviewed Original ResearchTypes of patientsWilson's diseaseMaintenance therapyInitial treatmentZinc maintenance therapyDouble-blind trialOpen-label studyNeurologic Wilson diseaseWeeks of treatmentDouble-blind designAnticopper drugNeurologic worseningTM armNeurologic deteriorationIntolerant patientsMost patientsNeurologic presentationNeurologic symptomsIll patientsSuch patientsUrine studiesBlind designBlind trialPatientsLabel study
2005
Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence
Schottenfeld RS, Chawarski MC, Pakes JR, Pantalon MV, Carroll KM, Kosten TR. Methadone Versus Buprenorphine With Contingency Management or Performance Feedback for Cocaine and Opioid Dependence. American Journal Of Psychiatry 2005, 162: 340-349. PMID: 15677600, DOI: 10.1176/appi.ajp.162.2.340.Peer-Reviewed Original ResearchConceptsCo-occurring cocaineDrug-free testOpioid dependenceMaintenance treatmentContingency managementOpioid agonist maintenance treatmentAgonist maintenance treatmentDaily sublingual buprenorphineEffects of buprenorphinePrimary outcome measureMixed-model repeated-measures analysisDouble-blind designUrine test resultsNarcotic treatment programsVoucher valueRepeated-measures analysisSublingual buprenorphineTreatment guidelinesIllicit opioidsUrine testsTreatment outcomesOutcome measuresSustained abstinenceWeek 13Buprenorphine
2004
Inositol for depressive disorders
Taylor M, Wilder H, Bhagwagar Z, Geddes J. Inositol for depressive disorders. Cochrane Database Of Systematic Reviews 2004, 2004: cd004049. PMID: 15106232, PMCID: PMC6984679, DOI: 10.1002/14651858.cd004049.pub2.Peer-Reviewed Original ResearchConceptsTreatment of depressionCochrane Controlled Trials RegisterControlled Trials RegisterTrials RegisterAdjunctive therapyDepressive disorderNeurosis Controlled Trials RegisterCochrane Collaboration DepressionAcceptability of treatmentDouble-blind designShort-term trialsAntidepressant medicationData collectionTherapeutic benefitAlternative treatmentReference listsAffective disordersEffective interventionsTerm trialsAdverse effectsTrialsPoor acceptabilityDepressionTreatmentDisorders
2003
Contrasting effects of citalopram and reboxetine on waking salivary cortisol
Harmer C, Bhagwagar Z, Shelley N, Cowen P. Contrasting effects of citalopram and reboxetine on waking salivary cortisol. Psychopharmacology 2003, 167: 112-114. PMID: 12605289, DOI: 10.1007/s00213-003-1417-y.Peer-Reviewed Original ResearchConceptsHPA axis activitySalivary cortisolAxis activitySelective noradrenaline re-uptake inhibitorNoradrenaline re-uptake inhibitorSelective serotonin re-uptake inhibitor citalopramConclusionsShort-term treatmentDifferent antidepressant medicationsHPA axis functionEffect of citalopramRe-uptake inhibitorsDouble-blind designShort-term treatmentBasal salivary cortisol levelsDiurnal salivary cortisolSalivary free cortisolSalivary cortisol levelsAntidepressant administrationRationaleAcute administrationReboxetine treatmentAntidepressant medicationAntidepressant treatmentAxis functionHPA axisAdrenal axis
2002
Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression
Boutros NN, Gueorguieva R, Hoffman RE, Oren DA, Feingold A, Berman RM. Lack of a therapeutic effect of a 2-week sub-threshold transcranial magnetic stimulation course for treatment-resistant depression. Psychiatry Research 2002, 113: 245-254. PMID: 12559481, DOI: 10.1016/s0165-1781(02)00267-6.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTreatment-resistant depressed patientsDepressed patientsTherapeutic effectActive repetitive transcranial magnetic stimulationStimulation parametersTreatment-resistant depressionDouble-blind designTranscranial magnetic stimulationLeft prefrontal cortexSham groupMagnetic stimulationStimulation courseRTMS stimulationPatientsSystematic followThreshold stimulationPrefrontal cortexFollowPre-set criteriaSignificant differencesStimulationWork daysWeeksConsecutive work days
1995
Tryptophan depletion and attenuation of cue-induced craving for cocaine
Satel SL, Krystal JH, Delgado PL, Kosten TR, Charney DS. Tryptophan depletion and attenuation of cue-induced craving for cocaine. American Journal Of Psychiatry 1995, 152: 778-783. PMID: 7726319, DOI: 10.1176/ajp.152.5.778.Peer-Reviewed Original ResearchConceptsCue-induced cravingTryptophan depletionPlacebo conditionPotent serotonin reuptake blockerCue exposureSerotonin reuptake blockersDouble-blind designAmino acid drinkVisual analogue ratingsCocaine-dependent patientsAnalogue ratingsReuptake blockerAcute reductionPlasma levelsSerotonergic systemMale inpatientsAcid drinkTryptophan levelsDrug usePatientsCocaine useCocaineRelapseCravingTest sessions
1993
Effect of caffeine on the recognition of and responses to hypoglycemia in humans.
Kerr D, Sherwin RS, Pavalkis F, Fayad PB, Sikorski L, Rife F, Tamborlane WV, During MJ. Effect of caffeine on the recognition of and responses to hypoglycemia in humans. Annals Of Internal Medicine 1993, 119: 799-804. PMID: 8379601, DOI: 10.7326/0003-4819-119-8-199310150-00005.Peer-Reviewed Original ResearchConceptsGlucose levelsHypoglycemic symptomsCaffeine consumptionCounter-regulatory hormone levelsHyperinsulinemic glucose clamp techniqueMiddle cerebral artery velocityLarge carbohydrate loadCerebral artery velocityAcute caffeine ingestionClinical Research CenterLevels of norepinephrineAwareness of hypoglycemiaCerebral blood flowDouble-blind designGlucose clamp techniqueLate postprandial periodPlasma glucose levelsLevels of epinephrineBrain glucose useCaffeine-free colaEffects of caffeineAcute ingestionSympathoadrenal activationArtery velocityPlasma glucose
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply